News

PipelineReview.com5h
European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
BASEL, Switzerland I July 23, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), ...
PipelineReview.com5h
BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
MORRISTOWN, NJ, USA I July 22, 2025 I The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its ...
PipelineReview.com20h
Diakonos Oncology Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating DOC1021 (dubodencel) for Glioblastoma
HOUSTON, TX, USA I July 22, 2025 I Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat ...
PipelineReview.com20h
Orbital Therapeutics Presents Non-Human Primate Data for In Vivo CAR-T Therapy with Potential Best-in-Class Profile for Autoimmune Disease
Full B Cell Depletion Achieved in Blood, Spleen, and Lymph Nodes in Non-Human Primate Study. Data Supports the Nomination of OTX-201, a Novel In Vivo CAR-T Therapy, as Orbital’s ...
PipelineReview.com21h
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
WOBURN, MA, USA I July 22, 2025 I Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel ...